A method of quantitating neutrophil adhesion is reported. This method creates a dynamic flow environment similar to that encountered in a blood vessel. It allows the investigation of neutrophil adhesion to either purified adhesion molecules (ligand) or endothelial cell substrate (HUVEC) in a context similar to the in vivo environment with sheer stress.
Neutrophil firm adhesion to endothelial cells plays a critical role in inflammation in both health and disease. The process of neutrophil firm adhesion involves many different adhesion molecules including members of the β2 integrin family and their counter-receptors of the ICAM family. Recently, naturally occurring genetic variants in both β2 integrins and ICAMs are reported to be associated with autoimmune disease. Thus, the quantitative adhesive capacity of neutrophils from individuals with varying allelic forms of these adhesion molecules is important to study in relation to mechanisms underlying development of autoimmunity. Adhesion studies in flow chamber systems can create an environment with fluid shear stress similar to that observed in the blood vessel environment in vivo. Here, we present a method using a flow chamber assay system to study the quantitative adhesive properties of human peripheral blood neutrophils to human umbilical vein endothelial cell (HUVEC) and to purified ligand substrates. With this method, the neutrophil adhesive capacities from donors with different allelic variants in adhesion receptors can be assessed and compared. This method can also be modified to assess adhesion of other primary cell types or cell lines.
Genetic variants in both β2 integrins and in ICAM ligands are now recognized to be associated with the development of autoimmune disease1,2. The determination of the functional consequences of these variants in cells derived from individuals with these variants is necessary for our understanding of how these variants contribute to autoimmune disease pathogenesis. Such functional studies allow for the determination of the mechanisms by which naturally occurring genetic variants shape the immune response in both health and disease. In the specific example of SLE, we now know that variants in ITGAM (CD11b) and its ligand, ICAM-1, strongly associate with development of disease1,2. Because neutrophils are critical in inflammatory responses, the quantitative study of neutrophil adhesion may provide mechanistic insights into how genetic variants in ITGAM/ICAM alter inflammation.
Neutrophil firm adhesion to endothelial cells (EC) is a highly regulated process and plays an essential role in inflammatory responses3,4. The firm adhesion of neutrophil follows initial neutrophil rolling and capture on the EC and ultimately can result in transmigration in vivo. These processes involve many different kinds of adhesion molecules, including ICAM-1, ICAM-2, P-Selectin, E-Selectin on the endothelial cells and β2 integrins on the neutrophil5-9. Thus, careful quantification of neutrophil adhesion from donors with different allelic variants of adhesion molecules will be important to understand the functional and pathological consequences of these genetic variants.
Experimental use of a flow chamber can create an in vitro environment with fluid shear stress similar to that observed in the blood vessel environment in vivo10-12. Indeed, a flow chamber assay coupled with human umbilical vein endothelial cell (HUVEC) can mimic the in vivo environment of a blood vessel. Using this method, one can study the overall cellular adhesive properties towards endothelial cell. In addition, the highly controlled environment of the flow chamber also allows assessment of cell binding to purified adhesion ligands such as ICAM-1 to facilitate the study of specific receptor-ligand interactions.
We present here a method utilizing a flow chamber adhesion assay system to study the adhesive properties of human peripheral blood neutrophils to HUVEC and to purified ligand substrates. Using this method with cells from donors expressing different adhesion molecule allelic variants allows us to assess how these genetic variants can alter human neutrophil firm adhesion.
All donors recruited for this study gave written informed consent and the study was approved by the University of Alabama at Birmingham Institutional Review Board.
1. HUVEC Initial Culture and Subculture
2. HUVEC Layer Preparation
3. Purified Ligand Coating
4. Neutrophil Separation (All Steps Performed at Room Temperature)
5. Flow Chamber Adhesion Assay
Examples of neutrophil binding to a purified ligand (ICAM-1/P-Selectin) coated flow chamber (Figure 2) or of neutrophil binding to a HUVEC coated flow chamber assay (Figure 3) are shown. As shown in the figures, neutrophils continue to accumulate/adhere to the coated surface or HUVEC under conditions of continuous flow. Under our typical experiment conditions, we can observe 50-70 human neutrophils firmly adhering to the coated surface or HUVEC during a four-minute recording period. However, allelic variants of neutrophil adhesion molecules, or allelic variants in the substrate (purified ligand or HUVEC), could substantially alter quantitative neutrophil adhesion14.
We have also assessed the time dependence of the neutrophil adhesion events observed in our studies. While we are maintaining constant flow conditions, it is possible that the adhesive properties of the cells change over time. However, over the relatively short time courses in our studies, we do not observe any consistent differences in the rate of adhesion over time. For example, assessing adhesion at the 1-2 minute time points compared to adhesion observed between the 3-4 min time points are not consistently different. Of course, if cells are being stimulated during the adhesion experiment, then changes in adhesive properties over time could be expected.
In our studies, we controlled for isolation induced neutrophil activation by intentionally priming the cells with low dose fMLP (10-8 M) for 10 min prior to study. Endothelial cells (HUVEC in our studies) also require prior activation to upregulate adhesion molecule expression for optimal leucocyte firm adhesion. In the absence of pre-treatment, endothelial cells (HUVECs) will support very little neutrophil adhesion. In our studies, we used 10 ng/ml TNFα treatment for 4-6 hr prior to use. IL-1β (10 ng/ml) and LPS (0.5-1 µg/ml) can also be used to pre-activate the endothelial cells. Importantly, untreated HUVEC can be used as negative control to ensure that cell adhesion is caused by specific (receptor-mediated) neutrophil-endothelial cell interactions. Alternatively, anti-receptor antibodies can be used to block specific receptors to assess specificity of adhesion.
Figure 1. Flow chamber configuration on the microscope stage. Please click here to view a larger version of this figure.
Figure 2. Screen shots from a sample video of neutrophils adhering to ICAM-1/P-Selectin coated surface at different time points (A: 0 time point, B: 1 min time point, C: 2 min time point, and D: 4 min time point). The concentration of ICAM-1 is 25 µg/ml and P-Selectin is 0.5 µg/ml. Neutrophil flow speed is 350 µl/min with neutrophil density at 500,000 cells/ml.
Figure 3. Screen shots from a sample video of neutrophils adhering to HUVEC coated surface at different time points (A: 0 time point, B: 1 min time point, C: 2 min time point, and D: 4 min time point). Neutrophil flow speed is 350 µl/ml with neutrophil density at 500,000 cells/ml.
Species | Location | Shear stress (dynes/cm2) |
Human | Common caroid artery | 11.6 |
Human | Branchial artery | 6.5 |
Human | Common femoral artery | 4.3 |
Human | Suprarenal aorta | 7.3 |
Human | Supraceliac aorta | 4.2 |
Human | Superficial fermoral artery | 4.4 |
Human | Venules | 0.5-5.0 |
Human | Retinal first arterioles | 40.2 |
Human | Retinal second arterioles | 0.001 |
Human | Retinal first venules | 23.2 |
Human | Retinal second venules | 0.43 |
Dog | Common caroid artery | 15.8 |
Rabbit | Common caroid artery | 23.3 |
Rat | Common caroid artery | 46.6 |
Mouse | Common caroid artery | 64.8 |
Dog | Common femoral artery | 9.8 |
Rabbit | Common femoral artery | 156.8 |
Rat | Common femoral artery | 65.9 |
Table 1. Sample shear stress in different organs and different species.
* summarized from references 13, 16, 19, and 20.
This protocol guides the separation and isolation of minimally activated neutrophils for the careful quantification of neutrophil adhesion under sheer stress conditions. Neutrophil adhesion is a critical process in inflammation. Because genetic variants in multiple molecules in this process have been demonstrated to predispose to the development of autoimmune disease1,2, an assay system capable of quantitatively assessing human neutrophil firm adhesion is required. The method described in this protocol allows for the careful and quantitative determination of the firm adhesive potential of neutrophils in a controlled in vitro environment under sheer stress. This method thus allows the direct comparison of quantitative neutrophil adhesion between genotyped individuals to determine the importance of genetic variation in adhesion molecules14.
Several steps in this method merit careful consideration to achieve highly quantitative and reproducible results. In the HUVEC preparation, it is critical to attain 100% cell confluence before using them in the flow chamber. For using surfaces coated with purified ligand, the substrate coating area should never be allowed to dry out to avoid denaturing the ligand. In addition, the preparation of human neutrophils is critical to the success of the experiment. Key issues in isolating neutrophils from blood include gently handling by minimizing vortexing to avoid activation, keeping the cells at room temperature (i.e. the blood should not be stored on ice and centrifugation steps should be performed at room temperature) and completing the isolation and the experiment in the least amount of time as possible. There are additional neutrophil isolation methods that can also be utilized to prepare cells for these assays17,18.
From a practical perspective, adhesion assays using freshly isolated human neutrophils should be initiated within 3-6 hr after participant phlebotomy. As neutrophils are extremely sensitive to handling, prolonged times between the blood draw and usage could affect assay results. Careful determination of neutrophil cell concentration prior to the flow chamber assay is also necessary to achieve accurate and reproducible results.
During the flow chamber assay, it is important to monitor the video recording carefully to ensure that the flow speed is consistent and there is no turbulence throughout the length of the experiment. Changes in flow speeds or the presence of turbulence would necessitate that the experiment be repeated. After the experiment, it is also important to assess the remaining neutrophils microscopically to ensure that the neutrophils are not clumping. Clumping at this point would indicate that the neutrophils have become activated which could significantly alter neutrophil density during the experiment.
The flow chamber creates a near homogeneous sheer stress within the chamber (τ=6Qμ/(wh2), where Q=flow rate, μ=dynamic viscosity, and w=width of the flow chamber, h=height of the flow chamber15). In our studies, we used a flow rate of 350 µl/min for neutrophil adhesion, which creates a sheer stress of 1.5 dynes/cm2 (w=0.25 cm, h=0.01 in., the viscosity of water at 37 °C (0.007 poise) was used as an approximation of the viscosity of RMPI media). For a specific flow chamber, one can change the flow rate to achieve different levels of sheer stress to mimic different physiological conditions. Typical physiologic shear stress in human blood vessels can ranges between 0.5-5.0 dynes/cm 13,16. Shear stress in other blood vessels and other animals were listed in Table 1113,16,19 20.
While our method has focused on the study of the adhesion of human neutrophils, this method is not limited to neutrophils and can easily be applied to adhesion or rolling studies of other cell types with simple modifications. Also, the substrates in this method can be changed for different purposes.
Although this protocol is easily adaptable to different studies, there are some limitations. The protocol as implemented here requires large number of primary cells for analysis. This may preclude analysis of primary cells from small animals. Additionally, the need to immobilize purified adhesion ligands in an active/available conformation may limit the range of ligands. The use of Fc-fusion proteins greatly enhances the chances of achieving proper ligand conformation on the plate surface. Nonetheless, our method has significant flexibility to allow the quantitative analysis of adhesion events. These studies will greatly enhance our understanding of adhesion receptor-ligand pairs, and the potential function importance of genetic variants in these proteins, in the pathogenesis of human diseases.
The authors have nothing to disclose.
This work is sponsored by the Lupus Research Institute (NY, NY), NIH P01-AR49084, NIH R21-DA026956 and NIH UL1-TR00165. We thank Dr. Robert P. Kimberly for his continued support.
Table of Reagents Materials | |||
Name of reagent | Company | Catalogue number | Comments |
0.25% Trypsin/EDTA | Life technologies | 25200-056 | with Phenol Red |
2X Trypsin inhibitor | Life technologies | R-002-100 | |
35mm tissue culture dish | Corning Inc. | 430165 | Standard Tissue Culture Treated Surface |
75cm2 tissue culture flask | Corning Inc. | 430641 | Standard Tissue Culture Treated Surface |
CCD camera | Dage-MTI | Model 300T-RC | |
Cell freezing container | Biocision | BCS-045 | |
EBM-2 | Lonza Inc. | CC-3156 | HUVEC growth basal medium |
EGM-2 Bulletkit | Lonza Inc | CC-4176 | HUVEC growth factors for basal medium |
FBS | Life technologies | 10082-147 | Certified, Heat Inactivated |
Gelatin | Sigma | G9391 | from bovine skin |
Hemacytometer | Fisher scientific | 02-671-51B | |
Fibronectin | Sigma | F2006 | from human plasma |
Flow chamber | Glyco Tech | 31-001 | Circular flow chamber for 35mm dishes |
fMLP | Sigma | 47729 | |
Histopaque-11191 | Sigma | 11191 | Heavy ficoll |
HUVEC | Lonza Inc. | CC-2517A | |
ICAM-1 | R&D systems | 720-IC | Fc chimera |
Lymphocyte separation medium | Mediatech Inc. | 25072CV | Light ficoll |
Microscope | Zeiss | Axiovert 100 | |
RPMI 1640 medium | Life technologies | 11875 | with L-Glutamine and Phenol Red |
Protein A | Sigma | P6031 | resuspend in PBS |
P-Selectin | R&D systems | 137-PS | Fc chimera |
Syringe pump | KD Scientific | KDS270 | |
TNF-a | Life technologies | PHC3015 | Recombinant Human Protein |
Trypan Blue Solution, 0.4% | Life technologies | 15250-061 |